SciClone Pharmaceuticals (Holdings) Limited

SEHK:6600 Rapporto sulle azioni

Cap. di mercato: HK$11.4b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

SciClone Pharmaceuticals (Holdings) Gestione

Gestione criteri di controllo 2/4

SciClone Pharmaceuticals (Holdings) Il CEO è Hong Zhao, nominato in Jun2020, e ha un mandato di 4.08 anni. la retribuzione annua totale è CN¥ 25.33M, composta da 32.6% di stipendio e 67.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.18% delle azioni della società, per un valore di HK$ 20.59M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.1 anni e 3.4 anni.

Informazioni chiave

Hong Zhao

Amministratore delegato

CN¥25.3m

Compenso totale

Percentuale dello stipendio del CEO32.6%
Mandato del CEO4.1yrs
Proprietà del CEO0.2%
Durata media del management2.1yrs
Durata media del Consiglio di amministrazione3.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Apr 02
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Dec 14
Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Jun 19
Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

May 31
SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Feb 17
Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Dec 02
Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Oct 04
We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Jul 27
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Jun 02
An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Hong Zhao rispetto agli utili di SciClone Pharmaceuticals (Holdings)?
DataCompenso totaleStipendioGuadagni aziendali
Dec 31 2023CN¥25mCN¥8m

CN¥1b

Sep 30 2023n/an/a

CN¥1b

Jun 30 2023n/an/a

CN¥953m

Mar 31 2023n/an/a

CN¥904m

Dec 31 2022CN¥17mCN¥8m

CN¥855m

Sep 30 2022n/an/a

CN¥844m

Jun 30 2022n/an/a

CN¥833m

Mar 31 2022n/an/a

CN¥878m

Dec 31 2021CN¥26mCN¥7m

CN¥923m

Sep 30 2021n/an/a

CN¥837m

Jun 30 2021n/an/a

CN¥779m

Mar 31 2021n/an/a

CN¥766m

Dec 31 2020CN¥29mCN¥7m

CN¥754m

Sep 30 2020n/an/a

CN¥817m

Dec 31 2019CN¥15mCN¥6m

CN¥615m

Compensazione vs Mercato: La retribuzione totale di Hong ($USD 3.48M ) è superiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 510.44K ).

Compensazione vs guadagni: La retribuzione di Hong è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Hong Zhao (61 yo)

4.1yrs

Mandato

CN¥25,334,000

Compensazione

Mr. Hong Zhao has been President and Chief Executive Officer at SciClone Pharmaceuticals (Holdings) Limited since June 24, 2020 and also serves as its Executive Director since June 24, 2020. Mr. Zhao serve...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Hong Zhao
CEO, President & Executive Director4.1yrsCN¥25.33m0.18%
HK$ 20.6m
Rongrong Pan
Company Secretaryless than a yearCN¥6.92m0.026%
HK$ 3.0m
Chihwen Shao
VP & Head of Technical Operations and Pharmacovigilance2.5yrsNessun datoNessun dato
Min Jia
VP & Head of Immunization Business Unitno dataNessun datoNessun dato
Mingxiang Wu
VP and Head of Market Access & Commercial Operation (MACO) Departmentno dataNessun datoNessun dato
Lianzong Wu
VP and Head of Registration & Pharmaceutical Affairs Departmentno dataNessun datoNessun dato
Li Mao
VP, GM of Research and Development & Chief Medical Officer2.1yrsNessun datoNessun dato
Min Wu
VP & Chief Business Development Officerless than a yearNessun datoNessun dato

2.1yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di 6600 è considerato esperto (durata media dell'incarico 2.1 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Hong Zhao
CEO, President & Executive Director4.1yrsCN¥25.33m0.18%
HK$ 20.6m
Rongrong Pan
Company Secretary1.2yrsCN¥6.92m0.026%
HK$ 3.0m
Daniel Vasella
Non-Executive Director3.9yrsCN¥658.00kNessun dato
Guoen Liu
Independent Non-Executive Director3.4yrsCN¥658.00kNessun dato
Zhenfu Li
Non-Executive Chairman4.1yrsNessun datoNessun dato
Wendy Hayes
Independent Non-Executive Director3.4yrsCN¥658.00kNessun dato
Yi-Hsien Lin
Non-Executive Director3.4yrsNessun datoNessun dato
Ping Chen
Independent Non-Executive Director3.4yrsCN¥658.00kNessun dato
Yushao Gu
Independent Non-Executive Director3.4yrsCN¥658.00kNessun dato

3.4yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 6600 sono considerati esperti (durata media dell'incarico 3.4 anni).